Inhalation of foreign material is an uncommon condition that occurs more often in dogs than cats. The main aim of this study was to describe signalment, diagnostic investigation, management and outcomes of dogs and cats with tracheobronchial foreign bodies (TBFBs) in four UK referral centres. Ninety-two dogs and 14 cats with a diagnosis of intraluminal TBFBs between January 2012 and July 2019 were included. Labrador retriever was the most commonly represented canine breed (22/92). Cough was the most common presenting complaint, occurring in 89/92 dogs and 9/14 cats. Summer seasonality was recorded in 74/88 dogs, but no feline seasonality was observed. Radiographic suspected TBFB location agreed with definitive location in 15/22 dogs and 2/2 cats. CT-suspected TBFB location and definitive location agreed in 45/46 dogs and 4/5 cats. Most common TBFB location was right caudal lobe bronchus in dogs (35/97) and trachea in cats (6/14). One of 100 canine TBFBs and nine of 14 feline TBFBs were non-vegetal. Single-attempt bronchoscopic retrieval was successful in 88/92 dogs and 13/14 cats. Surgical retrieval was performed in 4/92 dogs. All patients survived to discharge. This study suggests a pattern of canine TBFB seasonality in the UK. Imaging was useful to guide localisation, and CT appeared more accurate at predicting TBFB location than radiography in dogs. Bronchoscopic TBFB removal was commonly successful, with excellent survival rates. Presenting signs, patterns of seasonality, imaging findings, and management outcomes are useful to help clinical reasoning and decision management in the practical setting.

The most common bacterial isolates in dogs with pyothorax include mixed anaerobes, Enterobacteriaceae (especially Escherichia coli), Pasteurella spp., Streptococcus spp., and Staphylococcus spp. A fluoroquinolone with amoxicillin (±clavulanate) or a fluoroquinolone with clindamycin are the most commonly recommended empirical antimicrobials whilst pending bacterial culture of the pleural effusion. The aim of this study is to review and compare the pleural effusion culture and antimicrobial susceptibility results to the PROTECT ME poster and other published antimicrobial use guidelines. The medical records of 53 dogs diagnosed with pyothorax between 2014 and 2020 at two veterinary referral centres were reviewed. Information, including culture and susceptibility results, was assessed. Antimicrobial susceptibility panels varied; susceptibility to a particular antibiotic was calculated as a percentage of isolates tested against the same antibiotic. A total of 30 of 53 dogs (57.7%) had a positive pleural fluid culture. The most common isolates were Pasteurella species (23.3%), Escherichia coli (23.3%), and mixed anaerobes (20%). From the aerobic isolates, 73-83% were susceptible to a fluoroquinolone, 14/19 (74%) to amoxicillin, and 20/22 (91%) to potentiated amoxicillin. Resistance to clindamycin was documented in 9/13 (69%) aerobic isolates, with all Gram-negative bacteria (9/9) being resistant. The combination of potentiated amoxicillin with marbofloxacin would have been appropriate in most of the dogs (75-92.9%). This study shows a high rate of resistance to clindamycin, which is not a suitable option for monotherapy and may be less effective in combination therapy compared to potentiated amoxicillin.

AbstractBackgroundThrombocytopenia is a common laboratory abnormality in dogs, and numerous diseases have been associated with its development. Estimates for the sensitivity and specificity of the degree of reduction of platelet concentration for the diagnosis of primary immune‐mediated thrombocytopenia (pITP) have not been reported.ObjectivesTo report the prevalence of different causes of thrombocytopenia in dogs in the United Kingdom and to investigate the utility of platelet concentration to differentiate causes of thrombocytopenia.MethodsMedical records of 762 dogs with thrombocytopenia presented to seven referral hospitals from January 2017 to December 2018 were retrospectively reviewed. Cases were assigned into the following categories: pITP, infectious diseases, neoplasia, inflammatory/other immune‐mediated disorders and miscellaneous causes. The prevalence of the different categories was estimated, and platelet concentrations were compared. Receiver‐operating characteristic (ROC) curves were used to investigate the utility of platelet concentration to differentiate between causes of thrombocytopenia.ResultsThe most common disease category associated with thrombocytopenia was neoplasia (27.3%), followed by miscellaneous causes (26.9%), pITP (18.8%), inflammatory/immune‐mediated disorders (14.4%) and infectious diseases (12.6%). Dogs with pITP had significantly lower platelet concentrations (median 8 × 109/L, range: 0–70 × 109/L) than dogs in the other four categories. Platelet concentration was useful for distinguishing pITP from other causes of thrombocytopenia (area under ROC curve = 0.89, 95% confidence interval 0.87, 0.92), with a platelet concentration ≤12 × 109/L being 60% sensitive and 90% specific.ConclusionsSevere thrombocytopenia was highly specific for a diagnosis of pITP, which was more prevalent in this UK population of thrombocytopenic dogs compared with previous epidemiological studies. Conversely, the proportion of dogs with infectious diseases was lower than in previous reports from other locations.

Clinical abstract presented at BSAVA Congress 2023. See full text for abstract and see clinical abstract sessions for a recording of the presentation. Abstracts are presented as supplied and have not been edited.

Abstract Background Current reports about the use of splenectomy for the management of immune‐mediated hemolytic anemia (IMHA) or immune‐mediated thrombocytopenia (ITP) or both in dogs are limited. Objectives To retrospectively describe the use of splenectomy as part of the management for IMHA, ITP, and concurrent IMHA and severe thrombocytopenia (CIST) in dogs. It was hypothesized that splenectomy would be beneficial in allowing for reduction of dose of immunosuppressive drugs or discontinuation in 1 or more of these groups. Animals Seventeen client‐owned dogs (7 with IMHA, 7 with ITP, and 3 with CIST) were identified across 7 UK‐based referral hospitals from a study period of 2005 to 2016. Methods Data were collected retrospectively via questionnaires and included information about diagnosis, management and treatment response before and after splenectomy. Based on clinical outcome, treatment with splenectomy as part of the management protocol was classified as either successful or unsuccessful. Results Six of 7 dogs with ITP were managed successfully with splenectomy as part of their management protocol (3 complete and 3 partial responses), although 1 subsequently developed suspected IMHA. Of the 7 dogs with IMHA, splenectomy was part of a successful management protocol in 4 dogs (2 complete and 2 partial responses). In the CIST group, 1 case (1/3) responded completely to management with splenectomy as part of the management protocol. Conclusions and Clinical Importance Splenectomy was considered successful and well tolerated in most cases of isolated ITP. Whether there is a benefit of splenectomy in cases of IMHA and CIST could not be determined in the current study.

Abstract Clinical abstract presented at BSAVA Congress 2022. See full text for abstract and see clinical abstract sessions for a recording of the presentation. Abstracts are presented as supplied and have not been edited.

Oral presentations given during the BSAVA Abstract sessions 24-26 May 2021. The use of chlorphenamine as a pretransfusion treatment in dogs: good or bad prophylaxis; Treatment response and long-term prognosis in feline precursor-targeted immune-mediated anaemia; Causes of thrombocytopenia in dogs in the UK: a retrospective study of 765 cases; Multimodal therapies in canine primary immune mediated haemolytic anaemia (PIMHA): a descriptive study; Utility of C-reactive protein as a biomarker of remission in immune-mediated polyarthritis in dogs; Ultrasound-guided placement of a near-infrared fluorescent liquid soft tissue marker for fiducial marking of regions-of-interest during surgical procedures in a dog; Sensitivity and specificity of abdominal ultrasonography for the detection of ectopic ureters in urinary incontinent dogs; Clinical presentation, computed tomographic findings, treatment and outcome of canine cutaneous lymphoma; 10 dogs; Co-morbidities associated with diabetes mellitus in Burmese cats; New ways for clinicians to view old diseases: using data clustering to classify Cushing's syndrome; Hypothyroidism in dogs: epidemiology and clinical management in the first opinion population; Pulmonary hypertension in cats: causes and echocardiographic assessment; Development of atrial fibrillation and ventricular tachycardia in an adult cat with cor triatriatum sinister; Predictive value of cardiac remodeling on survival in dogs with persistent atrial standstill: the UK perspective; Association between neutering status and cardiac changes secondary to myxomatous mitral valve disease; Infectious myocarditis associated with transient myocardial thickening in a domestic short hair cat positive for bartonella henselae.

BACKGROUND:Radioactive iodine (RAI) is considered the gold standard treatment for feline hyperthyroidism. Currently exposure limits to radiation are regulated by national legislation, therefore the length of the isolation period in hospital for cats receiving radioactive treatment varies according to the place where the radioactive facility is located. The aim of this study was to establish when retained radioactivity decreases in cats receiving subcutaneous I-131 to a level that would allow discharge of cats from the hospital while being compliant with current United Kingdom legislation.METHODS:Clinical records of cats treated with subcutaneous I-131 were retrospectively reviewed. Radioactive emission rates were measured using an external probe. Retained radioactivity below 11 MBq at the point of discharge was required by the initial risk assessment to ensure that a 0.3 mSv dose constraint was maintained for owners following standard cat-owner contact restrictions. Average retained activity for each treatment regimen at the time of discharge was calculated. The biological half-life for iodine retention was also calculated.RESULTS:Overall, an end activity below 11 MBq was reached at day 11 in 49% of cats, and at day 13 in 91% of cats. These cats were allowed to be discharged according to UK legislation, as long as contact restrictions were applied at home for 2 weeks.CONCLUSION:Based on our study, an isolation period of 13 days before allowing discharge of cats treated with subcutaneous RAI (I-131) is compliant with current UK legislation.

Cutaneous and renal glomerular vasculopathy (CRGV) is an emerging disease in the UK, but its aetiology remains unclear. It is considered a thrombotic microangiopathy (TMA) in which the kidney and skin are the most commonly affected organs. We now document two cases of CRGV with brain lesions, which may have accounted for neurological signs displayed by these animals. The histopathological brain lesions were similar to TMA lesions in humans with thrombotic thrombocytopaenic purpura (TTP) and complement-mediated haemolytic uraemic syndrome (CM-HUS), in which the neurological signs are more associated with TMA than with any systemic disease or electrolyte imbalance. Fibrinoid necrosis in brain arterioles and associated lesions in these dogs were similar to those in human CM-HUS, indicating that the alternative complement pathway may play an important role in the pathophysiology of CRGV.

Objectives To evaluate clinical presentation, diagnosis, treatment and outcome of dogs diagnosed with detrusor urethral dyssynergy. Materials and Methods Multicentre (n = 3 UK referral clinics), retrospective, observational study. Database searches were performed (2007 to 2019) to identify dogs with detrusor urethral dyssynergy. Dogs with structural abnormalities or detectable neurological disorders affecting micturition were excluded. Clinical presentation, diagnostic procedures, treatment and outcome were evaluated. Results Thirty-five dogs were included. Middle-aged, large-breed, male neutered dogs were most frequently documented. Four female dogs were included. Fifteen breeds, including Labrador retrievers (8/35; 22.9%), golden retrievers (5/35;14.3%) and cross-breeds (5/35; 14.3%) were identified. Median duration of clinical signs was 152 days (range 0 to 1095). All dogs were dysuric at presentation with 17/35 (48.6%) reported to have an altered stream of urine and 17/35 (48.6%) to be stranguric. Follow-up data were available for 34 dogs (median 136 days, range 4 to 2188). Response was classified as good (20/34; 58.8%), partial (7/34; 20.5%) or poor (7/34; 20.5%). Overall time to response was known for 21 of 34 dogs (partial n = 6, good n = 15) with a median of 11 days (range 1 to 155). Four dogs had surgical intervention (castration n = 4, cystostomy tube n = 2). Three dogs were euthanased due to partial (n = 1) or poor (n = 2) response. Medications were discontinued in 11 of 20 (55.0%) dogs with a good response to therapy, two of these relapsed. Clinical Significance Detrusor urethral dyssynergy is an uncommon micturition disorder in dogs, in particular females. Medical therapy with or without surgery resulted in a favourable prognosis in the majority of dogs, although many require long-term medication.

BACKGROUND:One hundred seventy-eight dogs with cutaneous and renal glomerular vasculopathy (CRGV) were evaluated to further the understanding of the natural course of CRGV. CRGV, a form of thrombotic microangiopathy, can cause skin lesions and potentially acute kidney injury (AKI) with a high mortality rate.METHODS:Cases were submitted from multiple practices from 2012 until June 2019. Clinical histories and laboratory data were reviewed to describe the features of CRGV.RESULTS:Most cases (91%) occurred between November and May. Fifteen dogs (8.4%) with CRGV were in contact with another dog that developed skin lesions +/- AKI. Limb lesions were present on 144 dogs (80.9%) at presentation. Median time from appearance of a lesion to AKI was 3 days (range -4-45 days). Neurological signs occurred in 33 dogs (18.6%) including at presentation in 2 (1.1%). Systemic signs were present in 13 dogs prior to a skin lesion (7.3%). Non-steroidal anti-inflammatory drugs were prescribed prior to AKI identification in 92 of 170 dogs (54.1%). Thrombocytopenia was present in 115 of 137 (83.9%) of dogs.CONCLUSION:The timeframe over which AKI may develop is longer than previously reported, neurological signs can be identified at presentation or during hospitalisation, and thrombocytopenia is even more common than previously reported.

Abstract Background Serum bile acids (SBAs) are frequently measured in dogs. However, there is limited data comparing SBAs in different liver diseases diagnosed according to standardized histological criteria. Objectives To compare resting and postprandial SBAs, and determine their sensitivity and specificity, for various liver diseases in dogs. Animals Three hundred and forty‐one client‐owned dogs with suspected liver disease that had a liver biopsy and SBAs measured. Methods Multicenter retrospective study. Cases were classified according to standardized histological criteria. The sensitivity and specificity of resting and postprandial SBAs for the diagnosis of each liver disease, and all liver diseases combined, were calculated. Results The median resting SBAs were highest in dogs with cirrhosis (98.8 μmol/L; range, 6‐135) and congenital circulatory anomalies (CCa; 79.45 μmol/L; 0.3‐705). The highest median postprandial concentrations were found in CCa (126 μmol/L; 0‐726) and chronic hepatitis (CH; 54.3 μmol/L; 0‐260). Using the cut‐off value of 10 μmol/L, the highest sensitivities of resting SBAs were recorded in dogs with CCa (87.5%; 95% confidence interval, 76.8‐94.4) and CH (81.1%; 71.5‐88.6). The sensitivities of postprandial SBAs were the highest in cholangitis (100%; 47.8‐100.0) and CCa (91.1%; 78.8‐97.5). The specificities of resting and postprandial SBAs for all diseases were 49.3% (37.6‐61.1) and 29.7% (15.9‐47.0), respectively. Conclusions and Clinical Importance Postprandial SBAs are more sensitive but less specific than resting SBAs for the diagnosis of liver disease. There were dogs in all categories of liver disease with resting SBAs <10 and >90 μmol/L. Therefore, careful interpretation of both normal and elevated values is required.

Glomerular filtration rate (GFR) estimation is the gold standard for assessment of renal function, although the clinical utility of this test is unclear. To describe the clinical utility of GFR estimation in dogs. Medical records of 132 dogs that had serum iohexol clearance measured between 2012 and 2017. Iohexol clearance and clinical records were reviewed and submitting practices contacted to obtain outcome data. Dogs were classified into 4 groups based on the reason for performing GFR estimation: A1 (screening for pre-azotemic chronic kidney disease [CKD], n = 105), A2 (confirmation of azotemic CKD, n = 3), B (screening for pre-azotemic acute kidney injury, n = 19), and C (miscellaneous causes, n = 5). Descriptive review of the clinical utility of GFR estimation is provided. For dogs in Group A1, renal disease was diagnosed in 9/9 dogs with a GFR ≥40% decreased below the mean GFR of their body weight category, in 5/6 dogs with a ≥30% but <40% reduction in GFR and in 7/9 dogs with a ≥20% but <30% reduction in GFR. Glomerular filtration rate estimation is useful for the diagnosis of CKD before the onset of azotemia.

Cutaneous and renal glomerular vasculopathy (CRGV) has been recognized as a potentially life-threatening condition of dogs in the UK since 2012, although there was a single (non-azotaemic) case reported in the UK in 2000. Prior to that, CRGV was recognized in the 1980s in southern USA as a disease affecting solely racing greyhounds (which gave rise to the colloquial name of ‘Alabama rot’). CRGV manifests as ulcerative skin lesions, generally sparing the dorsum. It is variably associated with systemic signs including anaemia, thrombocytopenia and acute kidney injury, which, when it develops, is often severe and fatal. CRGV is characterized histopathologically as a thrombotic microangiopathy. To date in the UK, more than 230 dogs of varying breed and age have been humanely destroyed and histopathologically confirmed to be suffering from CRGV. The aetiology remains unknown, but the seasonal distribution (highest case incidence November–May each year) suggests that environmental or climatic factors may play a role in disease development. Further research to determine the aetiology and improve ante-mortem diagnostic testing, therapeutic options and preventive strategies is urgently needed.

The canine infectious respiratory disease complex (CIRDC) is an endemic worldwide syndrome involving multiple viral and bacterial pathogens. Traditionally, Bordetella bronchiseptica (Bb), canine adenovirus type 2 (CAV-2), canine distemper virus (CDV), canine herpesvirus (CHV) and canine parainfluenza virus (CPiV) were considered the major causative agents. Lately, new pathogens have been implicated in the development of CIRDC, namely canine influenza virus (CIV), canine respiratory coronavirus (CRCoV), canine pneumovirus (CnPnV), Mycoplasma cynos and Streptococcus equi subspecies zooepidemicus. To better understand the role of the different pathogens in the development of CIRDC and their epidemiological relevance in Europe, prevalence data were collected from peer-reviewed publications and summarized. Evidence of exposure to Bb is frequently found in healthy and diseased dogs and client-owned dogs are as likely to be infected as kennelled dogs. Co-infections with viral pathogens are common. The findings confirm that Bb is an important cause of CIRDC in Europe. CAV-2 and CDV recovery rates from healthy and diseased dogs are low and the most likely explanation for this is control through vaccination. Seroconversion to CHV can be demonstrated following CIRDC outbreaks and CHV has been detected in the lower respiratory tract of diseased dogs. There is some evidence that CHV is not a primary cause of CIRDC, but opportunistically re-activates at the time of infection and exacerbates the disease. The currently available data suggest that CIV is, at present, neither a prevalent nor a significant pathogen in Europe. CPiV remains an important pathogen in CIRDC and facilitates co-infection with other viral and bacterial pathogens. CnPnV and CRCoV are important new elements in the aetiology of CIRDC and spread particularly well in multi-dog establishments. M. cynos is common in Europe and is more likely to occur in younger and kennelled dogs. This organism is frequently found together with other CIRDC pathogens and is significantly associated with more severe respiratory signs. S. zooepidemicus infection is not common and appears to be a particular problem in kennels. Protective immunity against respiratory diseases is rarely complete, and generally only a reduction in clinical signs and excretion of pathogen can be achieved through vaccination. However, even vaccines that only reduce and do not prevent infection carry epidemiological advantages. They reduce spread, increase herd immunity and decrease usage of antimicrobials. Recommending vaccination of dogs against pathogens of CIRDC will directly provide epidemiological advantages to the population and the individual dog.

ObjectivesTo determine the proportion of dogs diagnosed with immune‐complex glomerulonephritis in a large cohort of UK dogs with clinical suspicion of glomerular disease in which renal histopathology, including routine light microscopy, transmission electron microscopy and immunofluorescence, had been performed. The second objective was to describe treatment and long‐term clinical outcome of dogs diagnosed with immune‐complex glomerulonephritis.Materials and MethodsSixty‐two UK dogs that underwent renal biopsies for investigation of suspected glomerulopathy (urine protein‐to‐creatinine ratio persistently >0.5) were included in this retrospective multicentre study. Signalment, clinico‐pathological abnormalities, histopathological diagnosis, treatment following diagnosis and survival were recorded.ResultsSeventeen (27%) of the dogs with suspected glomerular disease were diagnosed with immune‐complex glomerulonephritis and nine (53%) of these were still alive at the study end point, with a median follow‐up of 366 days (range 52 to 1299). Six dogs diagnosed with immune‐complex glomerulonephritis were treated with mycophenolate. Four received mycophenolate alone for immunosuppression and two received mycophenolate and chlorambucil; all these six dogs were alive at data collection [median follow‐up time 712.5 days (range 73 to 1299)]. Seven dogs diagnosed with immune‐complex glomerulonephritis did not receive immunosuppressive treatment; only one of these dogs was alive at study end point [median survival time 302 days (range 52 to 723)].Clinical SignificanceImmune‐complex glomerulonephritis may be less common in the UK than previously reported in North America and mainland Europe, reducing the likelihood of treatment modification following renal biopsy. Mycophenolate was the most commonly used immunosuppressant for cases of immune‐complex glomerulonephritis.

Cardiorespiratory signs are common in affected dogs, therefore thoracic imaging is critical 53 for diagnosing and monitoring disease. Descriptions of thoracic computed tomography (CT) 54 findings in dogs naturally infected with A. vasorum are currently lacking. Aims of this 55 multicentre, retrospective study were to findings in a group of dogs with confirmed disease, 56 determine whether any changes were consistent among dogs, and propose standardized terms 57 for describing thoracic CT findings. Nine UK-based referral centers’ clinical and imaging 58 databases were searched for dogs that had a confirmed diagnosis of A. vasorum, and had 59 undergone thoracic CT examination. Eighteen dogs, from seven of the centers, fulfilled the 60 inclusion criteria. The lung lobes were divided into the following three zones and the CT 61 changes described in each: pleural (zone 1), subpleural (zone 2) and peribronchovascular 62 (zone 3). The predominant abnormality was increased lung attenuation due to poorly defined 63 ground glass opacity or consolidation. There were regions of mosaic attenuation due to 64 peripheral bronchiectasis (6/18). Nine/18 (50%) dogs showed hyper attenuating nodules of 65 varying sizes with ill-defined margins. The distribution always affected zone 1,2 with varied 66 involvement of zone 3; this resulted in clear delineation between zones 2 and 3. 67 Tracheobronchial lymphadenomegaly was frequently noted. Findings were non-specific and 68 there was considerable overlap with other pulmonary conditions. However, authors 69 recommend that A. vasorum be considered a likely differential diagnosis for dogs with a 70 predominantly peripheral distribution of ground glass opacity or mosaic attenuation.

This article will review the most common hepatobiliary disorders in cats and dogs and consider their diagnosis and management. Clinical signs of liver disease can be very variable and include waxing and waning gastrointestinal or neurological signs. A number of animals are identified with a hepatopathy on “routine” blood work taken for other purposes. Unfortunately, given the liver’s large structural and functional reserve, specific clinical signs of liver disease, such as icterus, hypoglycaemia, coagulopathies, ascites or hepatic encephalopathy, are not typically seen until late in disease – when 70% to 80% of the functional liver mass is lost. Additionally, due to the liver’s dual blood supply, its high blood flow and the connection to other organs drained by portal circulation, the liver is also prone to secondary injury (“reactive hepatopathies”). Diagnosis can be achieved, in some cases, by a combination of compatible history, clinical signs, clinicopathological abnormalities and diagnostic imaging. However, definitive diagnosis, in most cases, ultimately relies on histological examination of liver tissue (liver biopsy). Treatment of liver disease depends on the type of hepatobiliary disorder, but, in general, involves the following steps: removal of the inciting agent, if present specific therapy nutrition general liver support therapy

Objectives To determine the time from treatment with a product containing imidacloprid 10 per cent/moxidectin 2.5 per cent spot-on (Advocate™), to dogs becoming negative for Angiostrongylus vasorum (A. vasorum). The authors hypothesised that most dogs would have resolution of A . vasorum within four weeks of treatment with Advocate™. Design Prospective, non-randomised, prepost treatment study. Setting Cases were enrolled from general practices along the southern coast of the United Kingdom. Participants Nine dogs completed the study and were enrolled if A. vasorum had been diagnosed based on a positive commercially available, in-clinic, serological A. vasorum antigen test (Angio Detect®) or Baermann performed at an external laboratory or both. Interventions The only treatment A. vasorum-positive dogs received was Advocate™ which was applied at the time of diagnosis and reapplied if necessary at four-weekly intervals until dogs tested negative by Angio Detect. Primary outcome measures Angio Detect® was performed and Advocate™ was reapplied at four-weekly intervals until dogs tested negative by this method. Secondary outcome measures Baermann was also performed at four-weekly intervals until dogs tested negative by this method. Results Application of Advocate™ was an effective treatment for A. vasorum infection in dogs and resulted in resolution of the infection, based on Angio Detect® testing and Baermann, within four weeks, in eight out of nine dogs. Post-treatment Angio Detect® testing was concordant with Baermann in seven of nine dogs. Conclusions Application of Advocate™ was an effective treatment for A. vasorum infection in dogs and resulted in resolution of the infection within four weeks in most dogs. Repeat Angio Detect® testing is recommended following treatment of A .vasorum to confirm resolution of the infection.

Seasonal outbreaks of cutaneous and renal glomerular vasculopathy (CRGV) have been reported annually in UK dogs since 2012, yet the aetiology of the disease remains unknown. The objectives of this study were to explore whether any breeds had an increased or decreased risk of being diagnosed with CRGV, and to report on age and sex distributions of CRGV cases occurring in the UK. Multivariable logistic regression was used to compare 101 dogs diagnosed with CRGV between November 2012 and May 2017 with a denominator population of 446,453 dogs from the VetCompass database. Two Kennel Club breed groups-hounds (odds ratio (OR) 10.68) and gun dogs (OR 9.69)-had the highest risk of being diagnosed with CRGV compared with terriers, while toy dogs were absent from among CRGV cases. Females were more likely to be diagnosed with CRGV (OR 1.51) as were neutered dogs (OR 3.36). As well as helping veterinarians develop an index of suspicion for the disease, better understanding of the signalment risk factors may assist in the development of causal models for CRGV and help identify the aetiology of the disease.